NO20054096L - Inhibitor for perioperativ blodsukkerforhoyelse - Google Patents

Inhibitor for perioperativ blodsukkerforhoyelse

Info

Publication number
NO20054096L
NO20054096L NO20054096A NO20054096A NO20054096L NO 20054096 L NO20054096 L NO 20054096L NO 20054096 A NO20054096 A NO 20054096A NO 20054096 A NO20054096 A NO 20054096A NO 20054096 L NO20054096 L NO 20054096L
Authority
NO
Norway
Prior art keywords
inhibitor
perioperative
amino acid
blood glucose
blood sugar
Prior art date
Application number
NO20054096A
Other languages
English (en)
Other versions
NO333498B1 (no
Inventor
Ippei Yamaoka
Yasuhiro Mitsumoto
Masako Doi
Tetsuya Fukunaga
Mitsuo Nakayama
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20054096L publication Critical patent/NO20054096L/no
Publication of NO333498B1 publication Critical patent/NO333498B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet en inhibitor for perioperativ blodsukkerforhøyelse som er kjennetegnet ved at den inneholder en forgrenet aminosyre, en forbindelse som kan omdannes til en forgrenet aminosyre in vivo eller en forbindelse hvortil en aminogmppe er overført fra en forgrenet aminosyre. Inhibitoren for perioperativ blodsukkerforhøyelse er nyttig som et legemiddel som er sikkert for den levende organismen iimbefattende mennesket, som inhiberer abnormal forhøyelse i blodglukosenivået forårsaket av anestesi, kirurgi, og så videre, og som muliggjør egnet blodsukkerkontroll når den administteres til en perioperativ pasient.
NO20054096A 2003-02-06 2005-09-02 Anvendelse av en forgrenet aminosyre for fremstilling av inhibitor for perioperativ blodsukkerforhoyelse NO333498B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003029260 2003-02-06
JP2003290792 2003-08-08
PCT/JP2004/001227 WO2004069236A1 (ja) 2003-02-06 2004-02-05 周術期血糖値上昇抑制剤

Publications (2)

Publication Number Publication Date
NO20054096L true NO20054096L (no) 2005-09-02
NO333498B1 NO333498B1 (no) 2013-06-24

Family

ID=32852677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054096A NO333498B1 (no) 2003-02-06 2005-09-02 Anvendelse av en forgrenet aminosyre for fremstilling av inhibitor for perioperativ blodsukkerforhoyelse

Country Status (9)

Country Link
US (1) US8273717B2 (no)
EP (1) EP1591116A4 (no)
JP (1) JP4589228B2 (no)
KR (1) KR20050102637A (no)
AU (1) AU2004210266B2 (no)
CA (1) CA2515505C (no)
NO (1) NO333498B1 (no)
TW (1) TWI349546B (no)
WO (1) WO2004069236A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5177785B2 (ja) * 2004-11-02 2013-04-10 味の素株式会社 周術期患者用薬剤
CN101287458A (zh) * 2005-10-12 2008-10-15 株式会社大塚制药工场 低血糖症状抑制用组合物
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
CA2649842C (en) * 2006-04-21 2015-02-17 Meiji Seika Kaisha, Ltd. Composition containing peptide as active ingredient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174979A4 (en) * 1984-03-01 1987-11-23 Vernon Erk METHOD FOR LOWERING THE BLOOD GLUCOSE LEVEL IN VERBELTIES.
JPS60255722A (ja) * 1984-05-30 1985-12-17 Otsuka Pharmaceut Factory Inc 糖尿病用アミノ酸輸液
JPS6130523A (ja) 1984-07-23 1986-02-12 Terumo Corp 還元糖、分岐鎖アミノ酸および電解質を含有する輸液剤
SE502414C2 (sv) * 1990-05-28 1995-10-16 Ljungqvist Olle Medical Ab Användning av glukos för framställning av lösning för preoperativ administrering samt infusionslösning därför
GB9517443D0 (en) * 1994-12-17 1995-10-25 Univ Nottingham Increasing creatine and glycogen concentration in muscle
US6008256A (en) * 1995-08-28 1999-12-28 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
CA2439293A1 (en) * 2001-03-05 2002-09-12 Stephen P. Ernest Enteral formulation
FR2822704B1 (fr) 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
US20040253227A1 (en) * 2002-09-11 2004-12-16 Martin Kenneth A. Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery

Also Published As

Publication number Publication date
KR20050102637A (ko) 2005-10-26
TWI349546B (en) 2011-10-01
US8273717B2 (en) 2012-09-25
WO2004069236A1 (ja) 2004-08-19
WO2004069236A9 (ja) 2005-03-10
CA2515505C (en) 2012-07-31
NO333498B1 (no) 2013-06-24
AU2004210266A1 (en) 2004-08-19
CA2515505A1 (en) 2004-08-19
US20060116426A1 (en) 2006-06-01
TW200505430A (en) 2005-02-16
JP4589228B2 (ja) 2010-12-01
EP1591116A4 (en) 2008-05-28
JPWO2004069236A1 (ja) 2006-05-25
EP1591116A1 (en) 2005-11-02
AU2004210266B2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2006119300A3 (en) Method of using oxidative reductive potential water solution in dental applications
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
BRPI0818191A2 (pt) métodos para a formação de vasos a partir de uma população de células de perfusato placentário e para o tratamento de um indivíduo tendo uma doença cardíaca ou vascular, distúrbio, condição ou insulficência
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
NO20076405L (no) Anvendelse av 24-nor-UDCA
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
MXPA05012392A (es) Tratamientos de ansiedad con ziprasidona.
NO20064964L (no) Behandling av svekket respiratorisk funksjon
NO20054096L (no) Inhibitor for perioperativ blodsukkerforhoyelse
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
WO2008009655A3 (de) Medizinische verwendung von n-phenylpropenoyl-aminosäurederivaten und verwandten verbindungen
US9943240B2 (en) Non-invasive method for measuring tissue perfusion state
BR112023024210A2 (pt) Comprimido efervescente orodispersível contendo budesonida para uso no tratamento de esofagite eosinofílica
Franklin Isolated systolic hypertension and the J-curve of cardiovascular disease risk
JP6583608B2 (ja) 高血圧ならびに血圧変動性増大を備えたモデル動物，およびこれを用いた評価方法
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
Petrenko et al. Clinical case of chronotherapy of arterial hypertension
Ahmeda et al. Effect of tempol and tempol plus catalase on intra-renal haemodynamics in spontaneously hypertensive stroke-prone (SHSP) and Wistar rats
WO2007076505A3 (en) Transferrin and transferrin-based compositions for diabetes treatment
WO2006020912A3 (en) Treatments for congestive heart failure

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees